Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
causation, CREXONT, judgement, logistic, Maryland, notification, Omalizumab, preemption, professional, unamortized, USDC, week, written, XOLAIR
Removed:
abstinence, addressed, affirmed, allege, appealed, approving, bellwether, certify, colchicine, Columbia, consent, conspired, consumer, contamination, cooperated, Corrupt, define, denying, DOJ, enrichment, entry, erosion, false, fixing, Guam, hospital, Influenced, joint, Mariana, municipal, National, negligence, neonatal, nuisance, Ohio, Opiate, preliminary, preparing, previously, proceeding, produced, protection, pursue, Racketeer, remuneration, syndrome, Territory, unjust, violation, Virgin, Zantac
Financial report summary
?Competition
Akorn • TherapeuticsMD • Lannett • Mylan • Pfizer • Cardinal Health • Teva Pharmaceutical Industries Limited • ANI Pharmaceuticals • Cencora • Sun Pharmaceutical IndustriesManagement Discussion
- Net revenue for the three months ended June 30, 2024 increased 17.1% from the prior year period primarily due to:
- •Growth in our Generics segment net revenue of $53.6 million, primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $16.7 million of year-over-year growth and other new generic products that contributed $36.2 million of year-over-year growth, and strong volume growth.
- •Growth in our AvKARE segment net revenue of $42.1 million, primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.